Driving Laws and Prescribed Cannabis: New South Wales

Why prescribed cannabis does not protect you at the roadside

"I have a prescription, so I'm fine to drive, right?" It is the question that comes up more than any other when prescribed cannabis meets road law, and the short answer is no. The longer answer is what this article is about.

New South Wales operates a zero-tolerance roadside drug testing regime for certain substances, and tetrahydrocannabinol (THC) is one of them. Holding a lawful prescription for a Schedule 8 controlled drug or a Schedule 4 prescription-only cannabis product does not exempt a driver from detection or prosecution under NSW road law. That gap between federal access law and state traffic law is real, it matters, and it catches people off guard.

The reason the gap exists is structural. Access to a medicine and permission to drive after taking it are decided by different bodies, under different legislation, asking different questions. One asks whether a product is suitable to supply. The other asks whether a substance is present in a driver. For a broader look at how those layers fit together, see our explainer on state versus federal drug regulation in Australia.

How NSW roadside drug testing works

Under the Road Transport Act 2013 (NSW) and the Drug Misuse and Trafficking Act 1985 (NSW), police are empowered to conduct oral fluid tests at random. The device tests for THC, methylamphetamine, MDMA, and cocaine. It does not test for impairment. It tests for presence.

That distinction is important. NSW law does not require a driver to be impaired. A positive oral fluid screen for THC, even at trace concentrations, is sufficient to trigger the offence of driving with a prescribed illicit drug present in your oral fluid or blood. The Roads and Maritime Services (now Transport for NSW) has published guidance on this, and the NSW Police Force enforces it without reference to whether the detected substance came from a lawful prescription.

A common mistake is to read "illicit" in the offence wording as meaning "obtained illegally". In practice the offence is framed around the substance and its presence, not around how the person came to have it. The law does not ask the roadside device, or the officer using it, to weigh up a prescription.

There is also a separate offence of driving under the influence (DUI), which does involve impairment assessment. But zero-tolerance testing runs alongside that framework, not as a substitute for it. A person can be charged under both provisions in the same incident.

Where THC sits in the Poisons Standard

At the federal level, THC is a Schedule 8 controlled drug under the Poisons Standard (the current instrument, formally the Standard for the Uniform Scheduling of Medicines and Poisons). If the terminology is new to you, our entries on the Poisons Standard and the SUSMP in more detail cover how scheduling works. Access to prescribed cannabis products in Australia flows through the TGA via two main pathways: the Special Access Scheme and the Authorised Prescriber pathway. A small number of products also sit on the ARTG.

Products containing only cannabidiol (CBD) above a certain purity threshold were down-scheduled to Schedule 4 in 2021, making low-dose CBD available via pharmacist supply without a prescription in some circumstances. But most medicinal cannabis products in clinical use contain THC, or a combination of THC and CBD, and those remain Schedule 8.

The federal scheduling framework governs supply. It says nothing about whether you can operate a vehicle. That's entirely a matter for state and territory traffic law.

The detection window problem

This is the part that I'd argue the public conversation handles worst. THC oral fluid detection windows vary considerably depending on the product, the dose, the delivery method, and individual pharmacokinetics. In plain terms, pharmacokinetics is how a body absorbs, distributes and clears a substance, and it differs from person to person. Smoked or vaped cannabis can leave detectable THC in oral fluid for several hours. Oral oil preparations, the most common form of prescribed medicinal cannabis in Australia, may produce lower peak oral fluid concentrations, but the science on precise detection windows for those formulations is still developing.

What the research does not support is any reliable "safe window" a driver can count on. And importantly, neither the NSW legislation nor the testing device makes any distinction between recreational and prescribed use.

It is easy to assume the dose-response relationship for oral fluid detection is well-characterised. It isn't, at least not to the level of precision that would let anyone confidently say "wait X hours after your prescribed dose and you'll test negative." That certainty doesn't exist in the published data. Anyone offering a neat number of hours is going beyond the evidence.

Workplace testing raises a related set of questions, since employers often use their own policies and methods. That is a separate framework from roadside enforcement, and we cover it in our piece on workplace drug testing and prescribed medicines.

What a valid prescription does and does not do

A valid Schedule 8 prescription issued under NSW law establishes that a person has lawfully obtained a controlled drug. It does not:

• Create an exemption from the zero-tolerance roadside testing offence
• Provide a statutory defence to a charge of driving with a prescribed illicit drug present in oral fluid or blood
• Alter the detection threshold applied by the oral fluid testing device

It may, in some circumstances, be a relevant consideration in sentencing, or in a DUI impairment matter where the court is weighing the overall picture. But that is a very different thing from a legal exemption. Transport for NSW and the NSW Police Force have both published materials noting that prescribed medicinal cannabis patients are not exempt from testing.

A second common mistake is treating a prescription label, a pharmacy printout or a letter from a prescriber as something that can be shown at the roadside to change the outcome. Those documents record lawful supply. They do not change what the device detects or what the offence requires.

This is one area where I think the policy framework has genuinely lagged the clinical access expansion. The number of Australians holding a valid medicinal cannabis prescription has grown substantially since 2017, the TGA's own data shows cumulative approvals well into the hundreds of thousands, and the roadside law has not moved to accommodate that. Whether it should is a legitimate policy debate. But right now, in NSW, the law is what it is. Our overview of medicinal cannabis access in NSW sets out the access side of the picture.

How other states compare, and the impairment science gap

Every Australian state and territory applies zero-tolerance THC testing for drivers. There is no jurisdiction in Australia that currently provides a statutory exemption for prescribed medicinal cannabis patients at roadside testing. Some states (Queensland, Victoria, South Australia and the ACT) have at various points reviewed or consulted on reform. None has yet enacted a prescription-based exemption that applies at the roadside testing stage. If you want the detail for a particular jurisdiction, we have separate pieces on Queensland, Victoria, South Australia and the Australian Capital Territory.

Victoria's inquiry into medicinal cannabis and driving (conducted by the Road Safety Committee) is probably the most detailed state-level examination of this question to date, and it stopped well short of recommending blanket exemptions, citing the impairment detection gap as an unresolved issue.

That gap is worth naming plainly. THC impairs driving at sufficient doses; that's supported by the evidence. But the relationship between oral fluid THC concentration and actual driving impairment is not linear, and it's not well enough characterised to support the kind of per-se impairment threshold used for alcohol (the 0.05 BAC standard). Cannabis tolerance, time since dose, delivery method, and whether the product is THC-dominant or includes significant CBD all interact in ways the current roadside device simply doesn't capture.

Some researchers argue the zero-tolerance approach overcounts impaired drivers while also, paradoxically, missing some genuinely impaired ones. That's a real tension. But the policy response to that tension hasn't arrived yet, at least not in NSW legislation.

What patients and prescribers should know

Prescribers operating under the Authorised Prescriber framework or the Special Access Scheme have an obligation to counsel patients on driving. The TGA has published guidance noting that prescribers should discuss with patients the legal implications of prescribed cannabis and vehicle operation. This isn't optional. It's part of the prescribing responsibility.

If you hold a prescribed cannabis product and drive in NSW, you are subject to the same zero-tolerance testing regime as everyone else. The only currently lawful position for a THC-containing prescription cannabis patient in NSW is not to drive until they can be confident no detectable THC remains in their oral fluid or blood, and given the uncertain detection windows, that means, in practice, working carefully with their prescriber on timing, and erring well on the side of caution.

Laws in this space are moving, even if slowly. Transport for NSW publishes updates, as does the NSW Police Force. Anyone directly affected should check those sources regularly rather than relying on what was true a year ago. The TGA's own driving page, listed below, is a sensible place to start, and the primary legislation is the best check on any claim you read secondhand, including this one.

Sources

• Medicinal Cannabis and Driving; Therapeutic Goods Administration (TGA)
• Drug Driving, Transport for NSW
• Road Transport Act 2013 (NSW), NSW Legislation
• Cannabis, Driving, and the Law: A Systematic Review; NCBI / PubMed Central

Marcus Hale, Regulatory researcher, TGA & access law